文献速递甲状腺疾病骨质疏松与钙磷/甲状旁腺

左甲状腺素对老年亚临床甲减患者骨骼的影响:TRUST随机试验嵌套研究

Skeletal Effects of Levothyroxine for Subclinical Hypothyroidism in Older Adults: A TRUST Randomized Trial Nested Study.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该研究为TRUST双盲安慰剂对照试验的预设嵌套子研究,纳入196例65岁以上社区居住的亚临床甲减患者,随机接受左甲状腺素剂量滴定或安慰剂模拟滴定。1年随访显示,左甲状腺素对腰椎和全髋骨密度、骨小梁评分及骨转换标志物均无显著影响。

要点

  • 老年亚临床甲减患者使用左甲状腺素1年未显著改变骨密度。
  • 骨小梁评分和骨转换标志物在组间也无显著差异。
  • 研究提示短期左甲状腺素治疗对老年亚临床甲减骨骼安全性良好。

核心结论

  • 在老年亚临床甲减患者中,左甲状腺素治疗1年对骨骼健康无影响。

研究设计与样本

  • TRUST双盲安慰剂对照试验的预设嵌套子研究,196例65岁以上社区居住的亚临床甲减患者随机接受左甲状腺素剂量滴定或安慰剂模拟滴定。

主要发现

  • 调整临床中心和性别后,上述结果仍无显著组间差异。

临床怎么用

  • 对于老年亚临床甲减患者,短期左甲状腺素治疗无需过度担忧骨密度下降或骨转换增加。

局限性

  • 随访时间仅1年,样本量196例,可能不足以检测微小骨骼变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Both thyroid dysfunction and levothyroxine (LT4) therapy have been associated with bone loss, but studies on the effect of LT4 for subclinical hypothyroidism (SHypo) on bone yielded conflicting results. OBJECTIVE: To assess the effect of LT4 treatment on bone mineral density (BMD), Trabecular Bone Score (TBS), and bone turnover markers (BTMs) in older adults with SHypo. DESIGN AND INTERVENTION: Planned nested substudy of the double-blind placebo-controlled TRUST trial. Participants with SHypo were randomized to LT4 with dose titration versus placebo with computerized mock titration. SETTING AND PARTICIPANTS: 196 community-dwelling adults over 65 years enrolled at the Swiss TRUST sites had baseline and 1-year follow-up bone examinations; 4 participants withdrew due to adverse events not related to treatment. MAIN OUTCOME MEASURES: One-year percentage changes of BMD, TBS, and 2 serum BTMs (serum CTX-1 [sCTX] and procollagen type 1 N-terminal polypeptide [P1NP]). Student's t-test for unadjusted analyses and linear regression adjusted for clinical center and sex were performed. RESULTS: Mean age was 74.3 years ± 5.7, 45.4% were women, and 19.6% were osteoporotic. The unadjusted 1-year change in lumbar spine BMD was similar between LT4 (+0.8%) and placebo-treated groups (-0.6%; between-groups difference +1.4%: 95% confidence interval [CI] -0.1 to 2.9, P = .059). Likewise, there were no between-group differences in 1-year change in TBS (-1.3%: 95% CI -3.1 to 0.6, P = .19), total hip BMD (-0.2%: 95% CI -1.1 to 0.1, P = .61), or BTMs levels (sCTX +24.1%: 95% CI -7.9 to 56.2, P = .14), or after adjustment for clinical centers and sex. CONCLUSIONS: Over 1-year levothyroxine had no effect on bone health in older adults with SHypo. REGISTRATION: ClinicalTrial.gov NCT01660126 and NCT02491008.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Gonzalez Rodriguez E, Stuber M, Del Giovane C, et al. Skeletal Effects of Levothyroxine for Subclinical Hypothyroidism in Older Adults: A TRUST Randomized Trial Nested Study. J Clin Endocrinol Metab. 2020. PMID: 31702015. doi:10.1210/clinem/dgz058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。